» Articles » PMID: 25808077

The Loss of BKV-specific Immunity From Pretransplantation to Posttransplantation Identifies Kidney Transplant Recipients at Increased Risk of BKV Replication

Overview
Journal Am J Transplant
Publisher Elsevier
Specialty General Surgery
Date 2015 Mar 27
PMID 25808077
Citations 31
Authors
Affiliations
Soon will be listed here.
Abstract

Quantification of BKV-load and BKV-specific immunity have been evaluated to monitor BKV-replication and outcomes in kidney transplant recipients (KTRs) with BKV-infection. However, it remains crucial to better understand how immune markers can predict the risk for later infection. We studied all KTRs between 2008 and 2011. Twenty-four KTRs were diagnosed with BKV-replication and a control group of 127 KTRs was used for comparison. Samples were collected before at +1, +2, and +3 months posttransplantation. BKV-specific and alloreactive T cells were measured using an interferon-γ Elispot assay. The extent of immunosuppression was quantified by lymphocyte subpopulations and interferon-gamma levels. KTRs with a loss of BKV-specific T cells directed to Large T-antigen from pretransplantation to posttransplantation were at increased risk of BKV-replication (p < 0.001). In contrast, KTRs with stable/rising BKV-specific T cells were more likely not to develop BKV-replication (p < 0.05). KTRs developing BKV-replication showed significantly lower CD3+, CD4+, CD8+ T cells and interferon-γ levels posttransplantation, but significantly higher alloreactive T cells (p < 0.05). Monitoring pretransplant and posttransplant BKV-specific T cells is suggested a sensitive marker to identify KTRs at increased risk of BKV-replication. Increased susceptibility to immunosuppression predisposes KTRs to a loss of protective BKV-specific immunity that results in impaired virus control and BKV-replication.

Citing Articles

Control of BKPyV-DNAemia by a Tailored Viro-Immunologic Approach Does Not Lead to BKPyV-Nephropathy Progression and Development of Donor-Specific Antibodies in Pediatric Kidney Transplantation.

Cioni M, Muscianisi S, De Cicco M, Basso S, Hirsch H, Fontana I Microorganisms. 2025; 13(1).

PMID: 39858816 PMC: 11767705. DOI: 10.3390/microorganisms13010048.


Cellular Immunity Against BK Polyomavirus in Kidney Transplant Recipients: A Comprehensive Review.

Al-Talib M, Skaria A, Griffin S Transpl Infect Dis. 2024; 27(1):e14401.

PMID: 39499036 PMC: 11827742. DOI: 10.1111/tid.14401.


Allogeneic CD4 T Cells Sustain Effective BK Polyomavirus-Specific CD8 T Cell Response in Kidney Transplant Recipients.

Dekeyser M, de Goer de Herve M, Hendel-Chavez H, Lhotte R, Scriabine I, Bargiel K Kidney Int Rep. 2024; 9(8):2498-2513.

PMID: 39156165 PMC: 11328547. DOI: 10.1016/j.ekir.2024.04.070.


BK Polyomavirus in Pediatric Renal Transplantation-What We Know and What We Do Not.

Chiodini B, Guillaume-Gentil P, Vanhomwegen C, Hennaut E, Lolin K, Tram N Biomedicines. 2024; 12(5).

PMID: 38791055 PMC: 11118040. DOI: 10.3390/biomedicines12051093.


Pretransplant BKV-IgG serostatus and BKV-specific ELISPOT assays to predict BKV infection after kidney transplantation.

Bae H, Jung S, Chung B, Yang C, Oh E Front Immunol. 2023; 14:1243912.

PMID: 37809095 PMC: 10551174. DOI: 10.3389/fimmu.2023.1243912.